Kaken Pharmaceutical to License FIBLAST Wound Healing Agent to Chinese Pharmaceutical.Tokyo, Japan, Dec 22, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kaken Pharmaceutical announced on December 20 that it has concluded a licensing agreement with Chinese pharmaceutical company Beijing Tide Pharmaceutical regarding FIBLAST Spray, which uses a recombinant recombinant /re·com·bi·nant/ (re-kom´bi-nant) 1. the new entity (e.g., gene, protein, cell, individual) that results from genetic recombination. 2. pertaining or relating to such an entity. See also under DNA. basic fibroblast growth factor Basic fibroblast growth factor, also known as bFGF or FGF2, is a member of the fibroblast growth factor family. In normal tissue, basic fibroblast growth factor is present in basement membranes and in the subendothelial extracellular matrix of blood (bFGF) and is indicated for wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by . Under the agreement terms, the Chinese pharmaceutical will be able to exclusively develop and sell Kaken's proprietary product FIBLAST Spray in China. Beijing Tide Pharmaceutical expects to obtain marketing approval and begin sales of FIBLAST Spray in 2010. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion